BioInvent Expands The Development Program for BI-1206 With A New Clinical Trial

Comments from the CEO: “During the third quarter of 2017, BioInvent has initiated preparations for a clinical trial with BI-1206 in combination with rituximab to investigate its potential as a treatment of relapsing, aggressive forms of Non-Hodgkin Lymphoma and indolent lymphomas.”

Comments from the CEO “During the third quarter of 2017, BioInvent has initiated preparations for a clinical trial with BI-1206 in combination with rituximab to investigate its potential as a treatment of relapsing, aggressive forms of Non-Hodgkin Lymphoma and indolent lymphomas. Our hypothesis is that BI-1206 can prevent the development of resistance to rituximab, which is today the standard-of-care treatment of these patient categories. A positive outcome of this trial, which is planned to start in H1 2018, would further increase the commercial attractiveness of our unique antibody BI-1206. The new study will give BioInvent an opportunity to more rapidly investigate the safety of the combined treatment as well as early signs of patient response.

MORE ON THIS TOPIC